Xofluza, a flu antiviral drug developed by Roche and Shionogi, is now approved in Europe for children age 1 and older. The European Commission decision expands the patient population for the drug, which was previously approved for treating adolescents and adults.
The company said Tuesday that a final analysis of its Phase IIb/III study of cabotegravir showed greater efficacy in HIV prevention than Gilead's Truvada. The study, among men and transgender women who have sex with men, was stopped in May following an interim analysis.
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
A Phase IIb/III study sponsored by NIAID is being stopped early after an interim analysis indicated that injected cabotegravir provided better protection than Gilead's Truvada.
The Financial Times reported Monday that the Japanese drugmaker would merge its UK operations with a Dutch subsidiary.
In exchange for ceding rights to develop, sell and market Akili's two lead products in Japan and Taiwan to Shionogi, Akili will receive $20 million upfront and up to $105 million in additional payments dependent on reaching certain development and commercial milestones.
An HIV drug candidate developed under a joint venture between GlaxoSmithKline (NYSE:GSK) and Japanese pharmaceutical company Shionogi is showing promise as a contender to take on a blockbuster drug from rival Merck (NYSE:MRK). Initial phase 3 clinical trial results for dolutegravir show the GSK-Shionogi compound matches Merck’s HIV treatment raltegravir. But dolutegravir’s advantage will be […]
At the Abarca Forward conference earlier this year, George Van Antwerp, managing director at Deloitte, discussed how social determinants of health and a personalized member experience can improve medication adherence and health outcomes.